Scientific Program

ISCORT 15

12.01.16 - 16.01.16, Eilat, Israel

The Annual Meeting of the Israeli Society for Clinical Oncology and Radiation Therapy
ISCORT wishes to express its gratitude to the following companies for their support of the 15th ISCORT Annual Meeting:

**Platinum Sponsor**
Roche Pharmaceuticals (Israel) Ltd

**Gold Sponsor**
BMS
JANSSEN
NOVARTIS
PFIZER

**Silver Sponsor**
ASTRAZENECA
BOEHRINGER – INGELHEIM
ELI LILLY
NEOPHARM
MSD
TEVA

**Bronze Sponsor**
ASTELLAS
BAYER
GSK
ISI
LAVI-MEDTECH
MEDILINE
MEDISON
MEDTECHNICA
MERCK
NANOSTRING TECHNOLOGIES
RAFA
SANOFI

**Organizing Committee**

| President: | Prof. Jacob Schachter |
| Medical Oncology Co-Chair: | Dr. Keren Rouvinov |
| Radiation Oncology Co-Chair: | Prof. Rami Ben-Yosef |

**Scientific Committee**

| Prof. Jamal Zidan, Chairman |
| Prof. Eyal Fenig |
| Prof. Irina Lazarev |
| Prof. Beatrice Uziely |
| Dr. Alexander Beny |
| Dr. Hadassah Goldberg |
| Dr. Maya Gottfried |
| Dr. Marc Wygoda |
| Dr. Noa Efrat Ben-Baruch |
| Dr. Abed Agbarya |
| Prof. Ofer Merimsky |
| Dr. Zvi Simon |
| Dr. Raanan Berger |

**Organizing Company**

I.M. Knasim Ltd.
Dear Friends,

Welcome to ISCORT-15, the 15th annual conference of the Israeli Society of Clinical Oncology and Radiotherapy, January 2016.

In the past few years, we have witnessed a significant change in modern oncologic therapy, and most noteworthy, the rise of immunotherapy. This new technology allows us to successfully treat a wide range of tumors, while at the same time, minimizing toxicity and improving quality of life. I have no doubt that this technology, which started with therapy for melanoma, and has since spread to many other forms of cancer, will eventually become the main platform for modern oncologic treatment.

This conference will give an opportunity to explore the latest developments in this dynamic field, and allow a center of excellence in this field to present their expertise. I am hopeful, that in the coming years, this will be an example for professionalism and excellence in all the different oncology tracts.

In addition, we will reveal the fascinating story behind the basic science oncology research done at the Ella Lemelbaum Institute for Melanoma, which resulted in the sale of its immuno-technology to the giant pharmaceutical company MERCK for $605,000,000. (Something maybe to inspire the young physicians among us).

At this year’s conference, we have introduced some new innovations, such as a “Best of Journals” session, which will start out the day, and “Tumor Board” sessions in various disciplines. There will also be parallel sessions for our colleagues from radiotherapy and physics.

We have tried to use only speakers who are members of ISCORT, since we feel that Israeli oncologists and researchers are on a world class level in almost all disciplines. Excellence is found here at home.

I would like to thank Professor Zidan Jamal, the Scientific committee chairman, and the members of the committee on reviewing the abstracts which were submitted, and to also thank Dr. Wilmos Mermershtain, the chairman of the society, and of course, as usual, to Miri Gomulka and I.M. Knasim, on the amazing organization.

Wishing everyone a great meeting,

Professor Jacob Schachter, Conference President
17:00-17:20 Opening ceremony
Greetings and best residents award
Moderator: Dr. Keren Rouvinov, Soroka Medical Center, Beer-Sheva, Israel
Speakers: Dr. Wilmosh Mermershtain, ISCORT President, Soroka Medical Center, Beer-Sheva, Israel
Mrs. Miri Ziv, CEO, Israel Cancer Association, Givataym, Israel
Prof. Jacob Schachter, Conference President, Sheba Medical Center, Ramat-Gan, Israel

17:20-18:05 The best of ISCORT
Moderator: Prof. Jamal Zidan, Ziv Medical Center, Zefat, Israel

17:25-17:35 Abstract # 19
Metformin (met) use and outcome of sunitinib (su) treatment (tx) in diabetic patients (pts) with metastatic renal cell carcinoma (mRCC)
Dr. Daniel Keizman, Meir Medical Center, Kfar-Saba, Israel

17:35-17:45 Abstract # 76
Somatostatin receptors in pancreatic ductal adenocarcinoma (PDAC): Expression profiling and identification of a novel receptor-directed small molecules
Dr. Ido Wolf, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel

17:45-17:55 Abstract # 7
Real-life analysis evaluating 1594 N0/Nmic breast cancer patients for whom treatment decisions incorporated the 21-gene Recurrence Score result: 5-year KM estimate for breast cancer specific survival with Recurrence Score results ≤ 30 is > 98%
Prof. Salomon M. Stemmer, Rabin Medical Center, Petach-Tikva, Israel

17:55-18:05 Discussion
Prof. Jamal Zidan, Ziv Medical Center, Zefat, Israel

18:05-19:05 Keynote Lectures
Moderator: Prof. Rami Ben-Yosef, Rambam Health Care Campus, Haifa, Israel

18:05-18:35 How to establish a center of excellence in oncology
Prof. Jacob Schachter, Sheba Medical Center, Ramat-Gan, Israel

18:35-19:05 Original drug development: From imagination to reality
Prof. Gal Merkel, Sheba Medical Center, Ramat-Gan, Israel

19:05-19:35 Keynote Lecture
Moderator: Prof. Gil Bar-Sela, Rambam Health Care Campus, Haifa, Israel
The immune system and cancer. The faithful policemen and the escape artist
Prof. Dan Aderka, Sheba Medical Center, Ramat-Gan, Israel

19:35-21:00 Dinner
**Wednesday, January 13, 2016**

08:30-09:30  **Best of Journals Session**  
**Moderators:** Dr. Amichay Meirovitz, Hadassah Hebrew University Medical Center, Jerusalem, Israel  
Dr. Maya Gips, Shaare Zedek Medical Center, Jerusalem, Israel  

08:30-08:50  **Breast cancer**  
Dr. Rinat Yerushalmi, Rabin Medical Center, Petach-Tikva, Israel  

08:50-09:10  **Melanoma**  
Dr. Ronnie Shapira-Frommer, Sheba Medical Center, Ramat-Gan, Israel  

09:10-09:30  **Radiotherapy**  
Dr. Marc Wygoda, Hadassah Hebrew University Medical Center, Jerusalem, Israel  

09:30-10:30  **General Session 1: Lung cancer**  
**Moderators:** Prof. Nir Peled Rabin Medical Center, Petach-Tikva, Israel  
Dr. Shoshana Keren Rosenberg, Lin/Carmel Medical Center, Haifa, Israel  

09:30-10:10  **Latest clinical advances with immunotherapy in lung cancer**  
Dr. Maya Gottfried, Meir Medical Center, Kfar-Saba, Israel  
Supported by BMS and MSD  

10:10-10:30  **Defining the standard of care in 1st line EGFR mut+ NSCLC**  
Dr. Abed Agbarya, Assuta Medical Center, Haifa, Israel  
Supported by BMS  

10:30-11:00  **Coffee Break**

11:00-12:00  **Tumor board—Lung cancer**  
Supported by Roche  
**Moderator:** Dr. Maya Gottfried, Meir Medical Center, Kfar-Saba, Israel  
**Presenters:**  
Medical oncologist: Dr. Abed Agbarya, Assuta Medical Center, Haifa, Israel  
Medical oncologist and pulmonologist: Prof. Nir Peled, Rabin Medical Center, Petach-Tikva, Israel  
**Panel:**  
Pathologist: Dr. Gilad Vainer, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel  
Medical oncologist: Prof. Ofer Merimsky, Tel-Aviv Sourasky Medical Center, Tel-Aviv  
Pulmonologist: Dr. Amir Onn, Sheba Medical Center, Ramat Gan  
Neuro-Oncologist: Dr. Felix Bukshtein, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel  
Radiation oncologist: Dr. Raphael Pfeffer, Assuta Medical Center, Tel Aviv, Israel  

12:00-12:30  **Abstracts session (1)**  
**Moderators:** Dr. Julia Dudnik, Soroka Medical Center, Beer-Sheva, Israel  
Dr. Mariana Wolner, Rambam Health Care Campus, Haifa, Israel  

12:00-12:10  **Abstract # 129**  
**Novel formulation of RNase and DNAse employing unique nanospheres to allow oral drug delivery and demonstrate anticancer activity**  
Prof. Hovav Nechushtan, Hadassah Hebrew University Medical Center, Jerusalem, Israel
12:10-12:20  Abstract # 98
NRG Oncology/RTOG 0937: Randomized phase II study comparing Prophylactic Cranial Irradiation (PCI) alone to PCI and consolidative Extracranial Irradiation for extensive disease small cell lung cancer (ED-SCLC)
Dr. Aaron M. Allen, Rabin Medical Center, Petach-Tikva, Israel

12:20-12:30  Abstract # 5
Evolution of randomized trials in advanced/metastatic soft tissue sarcoma: endpoint selection, surrogacy and quality of reporting
Dr. Alona Zer, Rabin Medical Center, Petach-Tikva, Israel

12:30-12:45  Pro: Dr. Ofer Caspi, Rabin Medical Center, Petach-Tikva, Israel
12:45-13:00  Con: Prof. Dan Aderka, Sheba Medical Center, Ramat-Gan, Israel
13:00-14:00  Lunch

14:00-15:00  General session 2: Immunooncology. Melanoma
Moderator: Prof. Jacob Schachter, Sheba Medical Center, Ramat-Gan, Israel

14:00-14:20  Immunooncology
Prof. Michal Lotem, Hadassah Hebrew University Medical Center, Jerusalem, Israel
Supported by BMS

14:20-14:40  Targeted treatment approaches in metastatic melanoma
Prof. Dirk Schadendorf, University Hospital Essen, Germany
Supported by Novartis

14:40-15:00  Quality of life assessment in cancer patients
Dr. Ronnie Shapira-Frommer, Sheba Medical Center, Ramat-Gan, Israel
Supported by Roche

15:00-15:20  Coffee Break

15:20-16:00  General session 3: Gastrointestinal cancers
Moderators: Prof. Ron Epelbaum, Rambam Health Care Campus, Haifa, Israel
Dr. Katerina Shulman, Hillel Yaffe Medical Center, Hadera, Israel

15:20-15:40  Treatment approach in metastatic colorectal cancer in 2016
Dr. Ayala Hubert, Hadassah Hebrew University Medical Center, Jerusalem, Israel

15:40-16:00  Clinical dilemmas in colorectal cancer: grey zone
Dr. Sofia Man, Soroka Medical Center, Beer-Sheva, Israel

16:00-17:00  Tumor board-Gastric cancer
Supported by Eli Lilly
Moderator: Prof. Baruch Brenner, Rabin Medical Center, Petach-Tikva, Israel
Panel: Medical oncologist: Dr. Ravit Geva, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel
Radiation oncologist: Dr. Slava Soyfer, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel
Medical oncologist: Dr. Efraim Idelevich, Kaplan Medical Center, Rehovot, Israel
Surgeon: Prof. Hanoch Kashtan, Rabin Medical Center, Petach-Tikva, Israel
**Wednesday, January 13, 2016 (Continued)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>19:00</td>
<td>Dinner</td>
</tr>
<tr>
<td>21:00</td>
<td>Social Event</td>
</tr>
</tbody>
</table>

**Thursday, January 14, 2016**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-9:30</td>
<td><strong>Best of Journals Session</strong>&lt;br&gt;<strong>Moderators:</strong> Dr. Rivka Katsnelson, Kaplan Medical Center, Rehovot, Israel&lt;br&gt;Dr. Daniela Katz, Hadassah Hebrew University Medical Center, Jerusalem, Israel</td>
</tr>
<tr>
<td>08:30-8:50</td>
<td><strong>Lung cancer</strong>&lt;br&gt;Prof. Samuel Ariad, Soroka Medical Center, Beer-Sheva, Israel</td>
</tr>
<tr>
<td>08:50-09:10</td>
<td><strong>Sarcoma</strong>&lt;br&gt;Prof. Ofer Merimski, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel</td>
</tr>
<tr>
<td>09:10-09:30</td>
<td><strong>Genitourinary cancers</strong>&lt;br&gt;Dr. Avivit Peer, Rambam Health Care Campus, Haifa, Israel</td>
</tr>
<tr>
<td>09:30-09:50</td>
<td><strong>Moderator:</strong> Prof. Bella Kaufman, Sheba Medical Center, Ramat-Gan, Israel&lt;br&gt;The use of big data in cancer care and treatment: integration of genomics and proteomics&lt;br&gt;Dr. Frank Ong, Executive Director of Medical Affairs, NANTHEALTH, USA&lt;br&gt;Supported by Teva</td>
</tr>
<tr>
<td>09:50-10:30</td>
<td><strong>General session 4: Breast cancer</strong>&lt;br&gt;<strong>Moderators:</strong> Prof. Beatrice Uziely, Hadassah Hebrew University Medical Center, Jerusalem, Israel&lt;br&gt;Dr. Ella Evron, Assaf Harofeh Medical Center, Zerifin, Israel</td>
</tr>
<tr>
<td>10:50-11:50</td>
<td><strong>Tumor board-Breast cancer</strong>&lt;br&gt;Supported by Roche&lt;br&gt;<strong>Moderator:</strong> Dr. Noa Efrat Ben-Baruch, Kaplan Medical Center, Rehovot, Israel&lt;br&gt;<strong>Panel:</strong> Medical oncologist: Prof. Tamar Peretz, Hadassah Hebrew University Medical Center, Jerusalem, Israel&lt;br&gt;Medical oncologist: Prof. Bella Kaufman, Sheba Medical Center, Ramat-Gan, Israel&lt;br&gt;Radiation oncologist: Dr. Raphael Pfeffer, Assuta Medical Center, Tel Aviv, Israel&lt;br&gt;Medical oncologist: Dr. Ella Evron, Assaf Harofeh Medical Center, Zerifin, Israel&lt;br&gt;Breast surgical-oncologist: Dr. Eran Sharon, Rabin Medical Center, Petach-Tikva, Israel&lt;br&gt;Radiologist: Dr. Miri Sklar-Levy, Sheba Medical Center, Ramat-Gan, Israel</td>
</tr>
<tr>
<td>Time</td>
<td>Session/Topic</td>
</tr>
<tr>
<td>------------</td>
<td>-------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>11:50-12:20</td>
<td>Abstracts session (2)</td>
</tr>
<tr>
<td>11:50-12:00</td>
<td>Abstract # 123 Unnecessary tests at diagnosis of early breast cancer among Israeli patients</td>
</tr>
<tr>
<td>12:00-12:10</td>
<td>Abstract # 124 Shared responsibility? Personal and physician factors influence compliance with screening mammography guidelines</td>
</tr>
<tr>
<td>12:10-12:20</td>
<td>Abstract # 91 Next Generation Spine Radiosurgery using Volumetric Intensity-Modulated Arc Treatment (VMAT)</td>
</tr>
<tr>
<td>12:20-13:00</td>
<td>Immunooncology. Plenary session</td>
</tr>
<tr>
<td>13:00-14:00</td>
<td>Lunch</td>
</tr>
<tr>
<td>14:00-14:40</td>
<td>General session 5: GU malignancies</td>
</tr>
<tr>
<td>14:00-14:20</td>
<td>The mechanism of development resistance to castration therapy in prostate cancer</td>
</tr>
<tr>
<td>14:20-14:40</td>
<td>Treatment approach in metastatic prostate cancer in 2016</td>
</tr>
<tr>
<td>14:40-15:30</td>
<td>Tumor board-Kidney cancer</td>
</tr>
<tr>
<td>15:30-15:50</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>15:50-16:30</td>
<td>Renal cell carcinoma</td>
</tr>
<tr>
<td>15:50-16:10</td>
<td>Quality of response in MRCC – does it really matter?</td>
</tr>
</tbody>
</table>
Update on the landscape of kidney cancer therapeutics
Dr. Emiliano Calvo START Madrid CIOCC, Spain
Supported by Novartis

Abstracts session (3)

Moderators: Prof. Hovav Nechushtan, Hadassah Hebrew University Medical Center, Jerusalem, Israel
Dr. Jair Bar, Sheba Medical Center, Ramat-Gan, Israel

Abstract # 120
Outcome of post prostatectomy salvage radiotherapy - analysis of 144 cases
Dr. Heloise Feredj, Hospital Saint-Louis, Paris, France

Abstract # 111
Circulating cell-free DNA levels in patients with metastatic renal cell carcinoma
Dr. Keren Rouvinov, Soroka Medical Center Beer-Sheva, Israel

Abstract # 42
Initial clinical experience with pembrolizumab in metastatic heavily pre-treated patients with solid cancers at the Sheba medical center
Dr. Raya Leibowitz-Amit, Sheba Medical Center, Ramat-Gan, Israel

Best of Journals Session
Moderators: Dr. Moshe Mishaeli, Meir Medical Center, Kfar-Saba, Israel
Dr. Nava Siegelmann-Danieli, Maccabi Health Services, Israel

Gastrointestinal malignancies
Dr. Ravit Geva, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel

Gynecologic malignancies
Prof. Tamar Safra, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel

Best grant proposal competition
Moderator: Dr. Raanan Berger, Sheba Medical Center, Ramat-Gan, Israel
Panel: Prof Jamal Zidan, Ziv Medical Center, Zefat, Israel
Prof Nissim Haim, Rambam Health Care Campus, Haifa, Israel
Prof Beatrice Uzielli, Hadassah Hebrew University Medical Center, Jerusalem, Israel

Deciphering the role of SLAMF6 in central nervous system immune response to neoplasia: A potential target for CNS immunotherapy
Dr. Jonathan E. Cohen, Hadassah Hebrew University Medical Center, Jerusalem, Israel

18F-FLT PET for early assessment of response to immune checkpoint inhibitors in solid tumor
Dr. Alona Zer, Rabin Medical Center, Petach-Tikva, Israel

Heparanase and chemotherapy resistance in ER positive breast cancer
Dr. Amir Sonnenblick, Hadassah Hebrew University Medical Center, Jerusalem, Israel
09:25-09:40 Vote and award best grant proposal award
09:40-09:50 Best published paper award 2015
Moderator: Prof. Jamal Zidan, Ziv Medical Center, Zefat, Israel
Supported by Pfizer
9:50-10:10 Moderator: Dr. Ora Rosengarten, Shaare Zedek Medical Center, Jerusalem, Israel
The role of PARP Inhibitors – Ovarian cancer and beyond
Prof. Bella Kaufman, Sheba Medical Center, Ramat-Gan, Israel
Supported by Astrazeneca

10:10-10:40 Abstracts session (4)
Moderators: Dr. Irina Lazarev, Soroka Medical Center, Beer-Sheva, Israel
Dr. Valeria Semenisty, Rambam Health Care Campus, Haifa, Israel

10:10-10:20 Abstract # 88
Partial splenic embolization for treating prolonged thrombocytopenia due to hypersplenism in metastatic cancer patients: local experience of our center
Dr. Maria Passhak, Rambam Health Care Campus, Haifa, Israel

10:20-10:30 Abstract # 117
Molecular profiling-selected treatment in metastatic gastric and esophageal cancer: Real-life clinical experience
Dr. Ofer Purim, Rabin Medical Center, Petach-Tikva, Israel

10:30-10:40 Abstract # 27
Identifying the presence and content of spiritual distress in Israel: An analysis of the applicability of American tools in Israel
Michael Schultz, Rambam Health Care Campus, Haifa, Israel

10:40-11:00 Coffee Break
11:00-11:30 Debate II
The Added Value of Second Opinion in Oncology
Moderator: Dr. Wilmosh Mermershtain, Soroka Medical Center, Beer-Sheva, Israel

11:00-11:15 Pro: Prof Moshe Inbar, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel

11:15-11:30 Con: Prof Yoram Cohen, Ben-Gurion University of the Negev, Beer-Sheva, Israel

11:30-11:50 Moderator: Dr. Ido Wolf, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel
Uncommon thread: rare tumors with targetable alterations and common tumors with uncommon alterations
Dr. Julia Elvin, Foundation Medicine, Boston, USA
Supported by Roche

11:50-12:20 Moderator: Dr. Hadassah Goldberg, Western Galilee Hospital, Nahariya, Israel
SWOG and the US National Clinical Trials Network: Potential International Participation
Prof. Charles D. Blanke, Chair of SWOG, Oregon Health Sciences University of Portland, USA

12:20-12:40 Moderator: Dr. Zvi Symon, Sheba Medical Center, Ramat-Gan, Israel
Abscopal effect or radiotherapy
Dr. Raphael Pfeffer, Assuta Medical Center, Tel Aviv, Israel
12:40-13:10  Abstracts session (5)

**Moderators:** Dr. Larisa Ryvo, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel
Dr. Bella Nisenbaum, Meir Medical Center, Kfar-Saba, Israel

12:40-12:50  Abstract # 102
A study to select rational therapeutics based on the analysis of matched tumor and normal biopsies in subjects with advanced malignancies (WINTER) - The Sheba Experience
Dr. Tal Sella, Sheba Medical Center, Ramat-Gan, Israel

12:50-13:00  Abstract # 32
High throughput screening of primary versus metastatic isogenic cell lines reveals a novel role for SNX 18 in migration of melanoma cells
Prof. Gal Merkel, Sheba Medical Center, Ramat-Gan, Israel

12:50-13:00  Abstract # 33
A 2-MicroRNA signature predicts response to adoptive cell transfer therapy in melanoma patients
Prof. Gal Merkel, Sheba Medical Center, Ramat-Gan, Israel

13:00-13:10  Closing remarks
Prof. Jacob Schachter, Conference President, Sheba Medical Center, Ramat-Gan, Israel

13:10-13:15  Lunch

14:00-15:00  ISCORT Assembly [Tarshish Hall, ground floor]

19:00-21:00  Dinner

21:00  Social Event
10:10-11:00  Case presentations
Presenter: Dr. Tomer Heres, Rambam Health Care Campus, Haifa, Israel
Panel: Prof. Gilad Amiel, Rambam Health Care Campus, Haifa, Israel
Dr. Avivit Neumann, Rambam Health Care Campus, Haifa, Israel
Dr. Yoav Lipsky, Assuta Health Care Campus, Tel-Aviv, Israel

11:00-11:30  Coffee break

11:30-13:00  Treatment approach in Hematology
Moderator: Dr. Efrat Landau, Sheba Medical Center, Ramat-Gan, Israel

11:30-11:50  Hematology perspective
Prof. Eldad Dan, Rambam Health Care Campus, Haifa, Israel

11:50-12:10  Radiotherapy perspective
Dr. Efrat Landau, Sheba Medical Center, Ramat-Gan, Israel

12:10-13:00  Case presentations
Presenter: Dr. Myroslav Lutzyk, Rambam Health Care Campus, Haifa, Israel
Panel: Prof. Eyal Fenig, Rabin Medical Center, Petach-Tikva, Israel
Dr. Inna Ospovat, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel
Dr. Eldad Dan, Rambam Health Care Campus, Haifa, Israel

13:00-14:30  Abstracts session (1)
Moderators: Dr. Ben Ayon, Sheba Medical Center, Ramat-Gan, Israel
Dr. Anet Wygoda, Hadassah Hebrew University Medical Center, Jerusalem, Israel

13:00-13:10  Can SBRT Salvage Patients with Lung Cancer Following Pneumonectomy?
Dr. Noga Kurman, Davidoff Cancer Center, Rabin Medical Center, Petach-Tikva, Israel

13:10-13:20  Pre-clinical Studies Of Metformin Reveal Radiosensitization For Human Small Cell Lung Cancer In Vitro But Apparent Antagonism In Vivo
Dr. T. Rabin, Departments of Radiation Oncology and Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA

13:20-13:30  Stereotactic Ablative Body Radiation (SABR) for stage I lung cancer in Israel: a retrospective single institution report
Dr. Sarit Appel, Sheba Medical Center, Ramat-Gan, Israel

13:30-13:40  Trimodality with concomitant chemo radiation to 60 Gy followed by planned surgery in selected locally advanced non small cell lung cancer
Dr. Sarit Appel, Sheba Medical Center, Ramat-Gan, Israel

Dr. A. Moore, Davidoff Cancer Center, Rabin Medical Center, Petach-Tikva, Israel

13:50-14:10  Should Advanced Radiotherapy Technology (VMAT) be Routinely Applied to Treat Sacral Bone Metastases?
Dr. Viacheslav Soyfer, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel

14:10-14:20  Radiation of Cardiac and Large Vessel Sarcoma
Dr. Limor Appelbaum, Hadassah Hebrew University Medical Center, Jerusalem, Israel

14:20-14:30  Is Contouring the Left Anterior Descending (LAD) Artery Necessary for Left Breast Patients? A Retrospective Comparison Between Treated and Revised Plans
Efrat Shekel, Assuta Medical Centers
<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00-08:40</td>
<td>Stereotactic radiosurgery developments in the treatment of brain metastases (Brain-Lab)</td>
</tr>
<tr>
<td></td>
<td>Dr. Daphne Levin, Asuta Health Care Campus, Tel-Aviv, Israel</td>
</tr>
<tr>
<td></td>
<td>Sponsored by ISI</td>
</tr>
<tr>
<td>08:45-09:25</td>
<td>Hyperthermia - Radiobiological and physical principles</td>
</tr>
<tr>
<td></td>
<td>Prof. Hans Crezee, AMC, Amsterdam, Netherlands</td>
</tr>
<tr>
<td>09:30-10:45</td>
<td>Locally advanced/recurrent breast cancer</td>
</tr>
<tr>
<td></td>
<td>Moderator: Dr. Merav Ben-David, Sheba Medical Center, Ramat-Gan, Israel</td>
</tr>
<tr>
<td>09:30-09:45</td>
<td>Surgery perspective</td>
</tr>
<tr>
<td></td>
<td>Prof. Shlomo Sneibaum, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel</td>
</tr>
<tr>
<td>09:45-10:15</td>
<td>Radiotherapy perspective (including clinical hyperthermia)</td>
</tr>
<tr>
<td></td>
<td>Prof. Greetjan van-Tienhoven, AMC, Amsterdam, Netherlands</td>
</tr>
<tr>
<td>10:15-10:45</td>
<td>Case presentation</td>
</tr>
<tr>
<td></td>
<td>Presenter: Dr. Shira Galper, Sheba Medical Center, Ramat-Gan, Israel</td>
</tr>
<tr>
<td></td>
<td>Dr. Limor Epelbaum, Hadassah Hebrew University Medical Center, Jerusalem, Israel</td>
</tr>
<tr>
<td></td>
<td>Panel: Prof. Greetjan van-Tienhoven, AMC, Amsterdam, Netherlands</td>
</tr>
<tr>
<td></td>
<td>Prof. Shlomo Sneibaum, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel</td>
</tr>
<tr>
<td></td>
<td>Dr. Noa Ben-Baruch, Kaplan Medical Center, Rehovot, Israel</td>
</tr>
<tr>
<td></td>
<td>Prof. Rami Ben-Yosef, Rambam Health Care Campus, Haifa, Israel</td>
</tr>
<tr>
<td>10:45-11:15</td>
<td>Coffee break</td>
</tr>
<tr>
<td>11:15-13:00</td>
<td>Locally advanced/recurrent pancreatic cancer + liver met’s</td>
</tr>
<tr>
<td></td>
<td>Dr. Yaacov Richard Lawrence, Sheba Medical Center, Ramat-Gan, Israel</td>
</tr>
<tr>
<td>11:15-11:45</td>
<td>Surgery perspective</td>
</tr>
<tr>
<td></td>
<td>Prof. Mendy Ben Haim, Shaare Zedek Medical Center, Jerusalem, Israel</td>
</tr>
<tr>
<td>11:45-12:15</td>
<td>Radiotherapy perspective</td>
</tr>
<tr>
<td></td>
<td>Prof. Greetjan van-Tienhoven, AMC, Amsterdam, Netherlands</td>
</tr>
<tr>
<td>12:15-13:00</td>
<td>Case presentations</td>
</tr>
<tr>
<td></td>
<td>Presenter: Dr. Haitam Nasralla, Rambam Health Care Campus, Haifa, Israel</td>
</tr>
<tr>
<td></td>
<td>Panel: Prof. Mendy Ben Haim, Shaare Zedek Medical Center, Jerusalem, Israel</td>
</tr>
<tr>
<td></td>
<td>Prof. Greetjan van-Tienhoven, AMC, Amsterdam, Netherlands</td>
</tr>
<tr>
<td></td>
<td>Prof. Ron Epelbaum, Rambam Health Care Campus, Haifa, Israel</td>
</tr>
<tr>
<td>13:00-13:30</td>
<td>Abstracts session (2)</td>
</tr>
<tr>
<td></td>
<td>Moderators: Dr. Sion Koren Rabin Medical Center, Petach-Tikva, Israel</td>
</tr>
<tr>
<td></td>
<td>Dr. Rachel Bar Daroma, Rambam Health Care Campus Haifa, Israel</td>
</tr>
<tr>
<td>13:00-13:10</td>
<td>A Dosimetric Comparison Between Volumetric Modulated Arc and 3D Treatment Plans</td>
</tr>
<tr>
<td></td>
<td>for Synchronous Bilateral Breast Patients</td>
</tr>
<tr>
<td></td>
<td>Dr. Levin D., Assuta Medical Centers</td>
</tr>
<tr>
<td>13:10-13:20</td>
<td>SRS in the treatment of brain metastases, a comparison between radiation techniques: DAT, VMAT and IMRT</td>
</tr>
<tr>
<td></td>
<td>Dr. Yasmin Korzets Ceder, Davidoff Cancer Center, Rabin Medical Center, Petach-Tikva, Israel</td>
</tr>
</tbody>
</table>
Thursday, January 14, 2016 (Continued)

13:20-13:30 Feasibility of scalp dose reduction during hippocampus-sparing whole brain radiotherapy
Dr. Haitam Nasrallah, Rambam Health Care Campus, Haifa, Israel

13:30-14:00 Lunch

Friday, January 15, 2016

08:00-09:30 Radiotherapy Educational Session

**Moderator:** Dr. Shahar Daniel, Rambam Health Care Campus, Haifa, Israel
Dr. Yaron Leibovitz, Soroka Medical Center, Beer-Sheva, Israel

**SFRT for oligometastases**
Dr. Aaron M. Allen, Rabin Medical Center, Petach-Tikva, Israel

**Radiation and secondary cancer**
Dr. Marc Wygoda, Hadassah Hebrew University Medical Center, Jerusalem, Israel

**Will TKI replace I131 in Thyroid Cancer?**
Dr. Aaron Popovtzer, Rabin Medical Center, Petach-Tikva, Israel

Sponsored by Medtechnica

09:30-09:40 A Novel Collimating Applicator for HDR Ocular Conjunctiva Treatment
Dr. Sion Koren, Davidoff Cancer Center, Rabin Medical Center, Petach-Tikva, Israel

09:40-09:50 Evaluation of a novel transmission detector as a reference chamber for use in beam measurements
Dan Epstein, Assuta Medical Centers

09:50-10:00 Statistical Process Control for VMAT Pre-Treatment Verification QA Using ArcCHECK and Mobius3D
Shlomi Alani, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel

10:00-10:10 Monte Carlo simulation of the Elekta VersaHD linac
Egor Borzov, Rambam Health Care Campus, Haifa, Israel

10:20-10:30 Room scatter effects in Total Skin Electron Therapy: a Monte Carlo study
Alexander Nevelsky, Rambam Health Care Campus, Haifa, Israel

10:30-10:40 Commissioning of the 8 MeV electron beam for TSEI
Shahar Daniel, Rambam Health Care Campus, Haifa, Israel

10:40-10:50 Do Checklists improve physician performance and patient safety?
Dr. Yaacov Lawrence, Sheba Medical Center, Ramat-Gan, Israel

10:50-11:00 Risk Management and safety in Radiotherapy: Based on the Radiation oncology safety course - Sep 2015
Ran Ben-Hur, Davidoff Cancer Center, Rabin Medical Center, Petach-Tikva, Israel
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00-11:10</td>
<td>A novel radiosurgery software for treating multiple brain metastases simultaneously in a single fraction - first clinical experience</td>
<td>Efrat Shekel, Assuta Medical Centers</td>
<td></td>
</tr>
<tr>
<td>11:10-11:20</td>
<td>Plan quality and efficiency comparison for brain metastasis treatments between Gamma Knife and Versa HD linac</td>
<td>Alexander Nevelsky, Rambam Health Care Campus, Haifa, Israel</td>
<td></td>
</tr>
<tr>
<td>11:20-11:30</td>
<td>Craniospinal irradiation: comparison between traditional and advanced irradiation techniques</td>
<td>Shahar Daniel, Rambam Health Care Campus, Haifa, Israel</td>
<td></td>
</tr>
<tr>
<td>11:30-12:00</td>
<td>Coffee Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00-13:15</td>
<td>Medical Physics - Closing Remarks and General Assembly</td>
<td>Dr. Alezra Dror, Sheba Medical Center, Ramat-Gan, Israel</td>
<td></td>
</tr>
<tr>
<td>13:15-14:00</td>
<td>Lunch</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
This program was printed with the support of Roche Pharmaceuticals (Israel) Ltd.